Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)

Single injection of 100 μg corifollitropin alfa administered under protocol P05690

Daily recFSH administered under protocol P05690

GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690

hCG 5,000 IU/USP or 10,000 IU/USP administered under protocol P05690

Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.

Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690

Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690

Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P05690